NBY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NovaBay Pharmaceuticals Inc (NBY) is not a strong buy for a beginner investor seeking long-term growth. Despite the recent price surge, the lack of positive financial performance, absence of strong trading signals, and neutral sentiment from hedge funds and insiders suggest that this stock does not align with the user's investment goals.
The MACD is positive at 0.532, indicating bullish momentum, but it is contracting. RSI is at 76.797, suggesting the stock is nearing overbought territory. Moving averages are converging, signaling indecision. Key resistance levels are at 1.857 and 2.058, while support levels are at 1.208 and 1.007.
The stock experienced a significant 22.64% price increase during the regular market session, which could indicate short-term bullish sentiment.
Hedge funds and insiders are neutral, and there is no recent congress trading data.
In Q4 2025, revenue remained stagnant at 0, net income increased to -26,596,000 (up 2094.39% YoY but still negative), EPS dropped to -1.34 (down 24.72% YoY), and gross margin fell to 0 (down 100% YoY).
No analyst ratings or price target changes available.
